Bifogade filer
Kurs
+3,49%
Likviditet
37,1 MSEK
Kalender
Est. tid* | ||
2025-10-22 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-18 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-08 | - | X-dag ordinarie utdelning BIOG B 1.95 SEK |
2025-05-08 | - | X-dag bonusutdelning BIOG B 4.95 |
2025-05-07 | - | Årsstämma |
2025-05-07 | - | Kvartalsrapport 2025-Q1 |
2025-02-12 | - | Bokslutskommuniké 2024 |
2024-10-22 | - | Kvartalsrapport 2024-Q3 |
2024-07-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag bonusutdelning BIOG B 5 |
2024-05-08 | - | X-dag ordinarie utdelning BIOG B 1.90 SEK |
2024-05-07 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-07 | - | Bokslutskommuniké 2023 |
2023-10-20 | - | Kvartalsrapport 2023-Q3 |
2023-07-21 | - | Kvartalsrapport 2023-Q2 |
2023-05-08 | - | X-dag bonusutdelning BIOG B 1.45 |
2023-05-08 | - | X-dag ordinarie utdelning BIOG B 1.45 SEK |
2023-05-05 | - | Årsstämma |
2023-05-05 | - | Kvartalsrapport 2023-Q1 |
2023-02-03 | - | Bokslutskommuniké 2022 |
2022-10-21 | - | Kvartalsrapport 2022-Q3 |
2022-07-22 | - | Kvartalsrapport 2022-Q2 |
2022-05-18 | - | Split BIOG B 1:5 |
2022-05-09 | - | X-dag bonusutdelning BIOG B 11.29 |
2022-05-09 | - | X-dag ordinarie utdelning BIOG B 3.63 SEK |
2022-05-06 | - | Årsstämma |
2022-05-06 | - | Kvartalsrapport 2022-Q1 |
2022-02-04 | - | Bokslutskommuniké 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-08-12 | - | Kvartalsrapport 2021-Q2 |
2021-05-07 | - | X-dag ordinarie utdelning BIOG B 3.41 SEK |
2021-05-06 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-02-04 | - | Bokslutskommuniké 2020 |
2020-11-25 | - | Extra Bolagsstämma 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-08-13 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning BIOG B 3.75 SEK |
2020-05-07 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-06 | - | Bokslutskommuniké 2019 |
2019-10-23 | - | Kvartalsrapport 2019-Q3 |
2019-05-09 | - | X-dag bonusutdelning BIOG B 5.95 |
2019-05-09 | - | X-dag ordinarie utdelning BIOG B 4.05 SEK |
2019-02-07 | - | Bokslutskommuniké 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-08-17 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | X-dag bonusutdelning BIOG B 4.69 |
2018-04-26 | - | X-dag ordinarie utdelning BIOG B 4.31 SEK |
2018-04-25 | - | Årsstämma |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-02-08 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-08-18 | - | Kvartalsrapport 2017-Q2 |
2017-05-04 | - | X-dag bonusutdelning BIOG B 4.34 |
2017-05-04 | - | X-dag ordinarie utdelning BIOG B 3.16 SEK |
2017-05-03 | - | Årsstämma |
2017-05-03 | - | Kvartalsrapport 2017-Q1 |
2017-02-10 | - | Bokslutskommuniké 2016 |
2016-10-25 | - | Kvartalsrapport 2016-Q3 |
2016-08-17 | - | Kvartalsrapport 2016-Q2 |
2016-05-11 | - | X-dag bonusutdelning BIOG B 1.97 |
2016-05-11 | - | X-dag ordinarie utdelning BIOG B 3.03 SEK |
2016-05-10 | - | Årsstämma |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-03-18 | - | Extra Bolagsstämma 2016 |
2016-02-12 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
2015-08-18 | - | Kvartalsrapport 2015-Q2 |
2015-05-08 | - | X-dag bonusutdelning BIOG B 1.54 |
2015-05-08 | - | X-dag ordinarie utdelning BIOG B 3.46 SEK |
2015-05-07 | - | Årsstämma |
2015-05-07 | - | Kvartalsrapport 2015-Q1 |
2015-02-12 | - | Bokslutskommuniké 2014 |
2014-10-22 | - | Kvartalsrapport 2014-Q3 |
2014-08-20 | - | Kvartalsrapport 2014-Q2 |
2014-05-07 | - | X-dag bonusutdelning BIOG B 3.65 |
2014-05-07 | - | X-dag ordinarie utdelning BIOG B 3.35 SEK |
2014-05-06 | - | Årsstämma |
2014-05-06 | - | Kvartalsrapport 2014-Q1 |
2014-02-12 | - | Bokslutskommuniké 2013 |
2013-10-23 | - | Kvartalsrapport 2013-Q3 |
2013-08-22 | - | Kvartalsrapport 2013-Q2 |
2013-04-29 | - | X-dag bonusutdelning BIOG B 5.85 |
2013-04-29 | - | X-dag ordinarie utdelning BIOG B 4.15 SEK |
2013-04-26 | - | Analytiker möte 2013 |
2013-04-26 | - | Årsstämma |
2013-04-26 | - | Kvartalsrapport 2013-Q1 |
2013-02-08 | - | Bokslutskommuniké 2012 |
2012-10-23 | - | Analytiker möte 2012 |
2012-10-23 | - | Kvartalsrapport 2012-Q3 |
2012-08-21 | - | Kvartalsrapport 2012-Q2 |
2012-05-09 | - | X-dag ordinarie utdelning BIOG B 1.26 SEK |
2012-05-09 | - | X-dag bonusutdelning BIOG B 2.74 |
2012-05-08 | - | Årsstämma |
2012-05-08 | - | Kvartalsrapport 2012-Q1 |
2012-02-10 | - | Bokslutskommuniké 2011 |
2011-11-17 | - | Kapitalmarknadsdag 2011 |
2011-10-25 | - | Kvartalsrapport 2011-Q3 |
2011-05-11 | - | X-dag bonusutdelning BIOG B 1.08 |
2011-05-11 | - | X-dag ordinarie utdelning BIOG B 0.92 SEK |
2011-05-10 | - | Årsstämma |
2011-05-10 | - | Kvartalsrapport 2011-Q1 |
2011-02-11 | - | Bokslutskommuniké 2010 |
2010-10-27 | - | Kvartalsrapport 2010-Q3 |
2010-08-17 | - | Kvartalsrapport 2010-Q2 |
2010-05-07 | - | X-dag bonusutdelning BIOG B 0.6 |
2010-05-07 | - | X-dag ordinarie utdelning BIOG B 0.90 SEK |
2010-05-06 | - | Kvartalsrapport 2010-Q1 |
2010-02-22 | - | Bokslutskommuniké 2009 |
2009-10-22 | - | Kvartalsrapport 2009-Q3 |
2009-08-18 | - | Kvartalsrapport 2009-Q2 |
2009-04-23 | - | X-dag ordinarie utdelning BIOG B 0.40 SEK |
2009-04-22 | - | Årsstämma |
2009-04-22 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.
Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in the region. Minapharm develops, manufactures and commercialises medicines ranging from small molecules to complex genetically engineered proteins, as well as develops and licenses advanced technologies in the field of proteins and also cell and gene therapy to global pharma players. Headquartered in Cairo, the company commercialises over 100 products. With a workforce of over 1,400 employees, Minapharm has established an integrated business model composed of international and regional subsidiaries.
"This agreement coincides with Minapharm's expansion programme towards nutritional supplements. BioGaia is a world leader in probiotics and hence, a perfect fit to our broad gastroenterology portfolio in a high demand region," says Dr. Wafik Bardissi, Chairman and CEO of Minapharm Pharmaceuticals.
"I am very happy to be able to extend our coverage in Africa by entering Egypt with a regional and professional partner," says Isabelle Ducellier, CEO of BioGaia.
Latest press releases from BioGaia
07.04.2021 Notice to attend the Annual General Meeting of BioGaia AB (publ)
31.03.2021 BioGaia publishes annual report for 2020
17.03.2021 BioGaia Invest (BGI) - a new subsidiary focusing on innovative investments to support the growth of BioGaia
Isabelle Ducellier, CEO: +46 8 555 293 00